
    
      SPIL1033 is subcutaneous injection is indicated as adjunctive therapy to improve glycemic
      control in patients with type 2 diabetes mellitus.

      In this study, efficacy and safety of SPIL1033 will be evaluated. Subjects will receive
      SPIL1033 or placebo, 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the
      remaining 20 weeks.
    
  